These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32329475)

  • 1. Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.
    Stultz LK; Hunsucker A; Middleton S; Grovenstein E; O'Leary J; Blatt E; Miller M; Mobley J; Hanson PK
    Metallomics; 2020 Jun; 12(6):876-890. PubMed ID: 32329475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae.
    Stevens SK; Strehle AP; Miller RL; Gammons SH; Hoffman KJ; McCarty JT; Miller ME; Stultz LK; Hanson PK
    Mol Pharmacol; 2013 Jan; 83(1):225-34. PubMed ID: 23090979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in S. cerevisiae.
    Bierle LA; Reich KL; Taylor BE; Blatt EB; Middleton SM; Burke SD; Stultz LK; Hanson PK; Partridge JF; Miller ME
    PLoS One; 2015; 10(9):e0138085. PubMed ID: 26375390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
    Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
    J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in Saccharomyces cerevisiae.
    Singh V; Azad GK; Reddy M A; Baranwal S; Tomar RS
    Eur J Pharmacol; 2014 Aug; 736():77-85. PubMed ID: 24797784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
    Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
    J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae.
    Singh V; Azad GK; Mandal P; Reddy MA; Tomar RS
    FEBS Lett; 2014 Mar; 588(6):1044-52. PubMed ID: 24561198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
    Webb MI; Walsby CJ
    Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).
    Hummer AA; Heffeter P; Berger W; Filipits M; Batchelor D; Büchel GE; Jakupec MA; Keppler BK; Rompel A
    J Med Chem; 2013 Feb; 56(3):1182-96. PubMed ID: 23282017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
    Lentz F; Drescher A; Lindauer A; Henke M; Hilger RA; Hartinger CG; Scheulen ME; Dittrich C; Keppler BK; Jaehde U;
    Anticancer Drugs; 2009 Feb; 20(2):97-103. PubMed ID: 19209025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
    Hartinger CG; Jakupec MA; Zorbas-Seifried S; Groessl M; Egger A; Berger W; Zorbas H; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Oct; 5(10):2140-2155. PubMed ID: 18972504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1
    Richert M; Trykowski G; Walczyk M; Cieślak MJ; Kaźmierczak-Barańska J; Królewska-Golińska K; Sobczak JW; Biniak S
    Dalton Trans; 2020 Dec; 49(46):16791-16800. PubMed ID: 33174575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.
    Kapitza S; Pongratz M; Jakupec MA; Heffeter P; Berger W; Lackinger L; Keppler BK; Marian B
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):101-10. PubMed ID: 15503135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.